Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 9/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 9/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 9/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 9/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540542 | 0.98 | CASP3 (0.48) | CASP3SENP8SENP7SENP6PCSK9 | |
| SCHEMBL5542728 | 0.94 | CASP3 (0.52) | CASP3SENP8SENP7SENP6PCSK9 | |
| SCHEMBL5537849 | 0.88 | TLR8 (0.44) | NPC1RAB9ASMN1; SMN2TLR8S1PR4 | |
| SCHEMBL5545581 | 0.88 | RAB9A (0.49) | CASP3SENP8SENP7SENP6PCSK9 | |
| SCHEMBL5946928 | 0.85 | CASP3 (0.46) | CASP3SENP8SENP7SENP6PCSK9 | |
| SCHEMBL22926235 | 0.84 | SMN1; SMN2 (0.49) | CASP3SENP8SENP7SENP6PCSK9 | |
| SCHEMBL2443034 | 0.84 | CASP3 (0.51) | CASP3SENP8SENP7SENP6PCSK9 | |
| SCHEMBL14859131 | 0.82 | CASP3 (0.45) | CASP3SENP8SENP7SENP6PCSK9 | |
| SCHEMBL5946675 | 0.82 | RAB9A (0.68) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL10383965 | 0.82 | CASP3 (0.45) | CASP3SENP8SENP7SENP6PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CASP3 1021/4885SENP8 4471/4885SENP7 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.